Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05442580 · ClinicalTrials.gov registry record · Phase 1
CART-38 in Adult AML and MM Patients
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT05442580: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT05442580 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05442580, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38 cells".
Interventions
- DRUG Cyclophosphamide
- DRUG 3x10(6) CART-38 cellls
- DRUG 7x10(5) CART-38 cells
- DRUG 7x10(6) CART-38 cells
- DRUG 3x10(7) CART-38 cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2025-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05442580
The ClinicalTrials.gov registry entry for NCT05442580 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05442580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05442580 about?
NCT05442580 is a clinical study titled "CART-38 in Adult AML and MM Patients". This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myelom...
What is the current status of trial NCT05442580?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2023-05-30. Estimated completion is 2025-02-09.
What interventions are being tested in trial NCT05442580?
The interventions under investigation include: Cyclophosphamide (DRUG), 3x10(6) CART-38 cellls (DRUG), 7x10(5) CART-38 cells (DRUG), 7x10(6) CART-38 cells (DRUG), 3x10(7) CART-38 cells (DRUG).
Who is sponsoring clinical trial NCT05442580?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.